Get the Stockscreener App
10.37
0.19%
0.02
After Hours:
10.29
-0.08
-0.77%
Vir Biotechnology Inc stock is traded at $10.37, with a volume of 1.21M.
It is up +0.19% in the last 24 hours and up +21.00% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$10.35
Open:
$10.59
24h Volume:
1.21M
Relative Volume:
0.37
Market Cap:
$1.67B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-3.2776
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
-3.53%
1M Performance:
+21.00%
6M Performance:
+73.41%
1Y Performance:
+64.86%
1-Day Range:
$10.00
$10.64
1-Week Range:
$10.00
$11.66
52-Week Range:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.37 | 1.67B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology launches $200M public stock offering - MSN
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace
Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks
Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co
Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey
Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st
Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co
Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat
Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com South Africa
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - Insider Monkey
Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey
8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey
Vir Biotechnology, Inc. ($VIR) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Sanofi (SNY) Benefits from Vir Biotechnology's Collaboration wit - GuruFocus
Vir Biotechnology closes $240M Astellas deal for cancer drug By Investing.com - Investing.com Australia
Vir Biotechnology, Inc. Receives $240 Million Upfront Payment and $75 Million Equity Investment from Astellas - marketscreener.com
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatmen - PharmiWeb.com
Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy - Contract Pharma
Vir Biotechnology (NASDAQ: VIR) sets 2026 meeting and pay vote - Stock Titan
Vir Biotechnology closes $240M Astellas deal for cancer drug - Investing.com
Vir Biotechnology closes $240 million Astellas collaboration deal - StreetInsider
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer - Business Wire
Vir Biotechnology Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Vir Biotechnology Rings the Closing Bell - Nasdaq
A Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial Milestone - Yahoo Finance
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer - BioSpace
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Vir Biotechnology doses first patient in VIR-5500 expansion trial By Investing.com - Investing.com Australia
Vir Biotechnology (VIR) Advances Phase 1 Trial with First Patien - GuruFocus
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-ta - PharmiWeb.com
Vir Biotechnology doses first patient in VIR-5500 expansion trial - Investing.com
Vir Biotech CEO Stock Sale: $664K Transaction in April 2026News and Statistics - IndexBox
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 - AOL.com
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 - The Motley Fool
VIR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vir Biotechnology Announces Upcoming Chief Medical Officer Transition - TipRanks
Vir Biotechnology (NASDAQ: VIR) Chief Medical Officer to step down April 24 - Stock Titan
Vir Biotechnology, Inc. Announces Step Down of Mark Eisner as Executive Vice President and Chief Medical Officer, Effective April 24, 2026 - marketscreener.com
Quarterly Risk: Can Vir Biotechnology Inc be recession proof2026 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Vir Biotechnology (VIR) Leading with Its BiTEs Therapy - Insider Monkey
Vir Biotechnology’s CMO Change Already Reflected in Valuation—Attention Shifts to Execution Risks for VIR-5500 - Bitget
Aberdeen Group plc Sells 135,688 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):